167 related articles for article (PubMed ID: 20643726)
1. Lack of association between acellular pertussis vaccine and seizures in early childhood.
Huang WT; Gargiullo PM; Broder KR; Weintraub ES; Iskander JK; Klein NP; Baggs JM;
Pediatrics; 2010 Aug; 126(2):263-9. PubMed ID: 20643726
[TBL] [Abstract][Full Text] [Related]
2. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
[TBL] [Abstract][Full Text] [Related]
3. A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization.
Zangwill KM; Eriksen E; Lee M; Lee J; Marcy SM; Friedland LR; Weston W; Howe B; Ward JI
Pediatrics; 2008 Dec; 122(6):e1179-85. PubMed ID: 19047220
[TBL] [Abstract][Full Text] [Related]
4. Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection.
Heininger U; Stehr K; Christenson P; Cherry JD
Clin Infect Dis; 1999 Mar; 28(3):602-4. PubMed ID: 10194085
[TBL] [Abstract][Full Text] [Related]
5. Effects of a minimum interval immunization schedule for diphtheria and tetanus toxoids and acellular pertussis vaccination during a pertussis outbreak.
Bronson-Lowe D; Anderson SM
Arch Pediatr Adolesc Med; 2009 May; 163(5):417-21. PubMed ID: 19414686
[TBL] [Abstract][Full Text] [Related]
6. Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
Zepp F; Knuf M; Habermehl P; Mannhardt-Laakmann W; Howe B; Friedland LR
J Pediatr; 2006 Nov; 149(5):603-610. PubMed ID: 17095328
[TBL] [Abstract][Full Text] [Related]
7. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.
Langley JM; Predy G; Guasparini R; Law B; Diaz-Mitoma F; Whitstitt P; Tapiero B; Dionne M; Tomovici A; Mills E; Halperin SA
Vaccine; 2007 Jan; 25(6):1121-5. PubMed ID: 17045366
[TBL] [Abstract][Full Text] [Related]
8. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.
Schmitt-Grohé S; Stehr K; Cherry JD; Heininger U; Uberall MA; Laussucq S; Eckhardt T
Dev Biol Stand; 1997; 89():113-8. PubMed ID: 9272341
[TBL] [Abstract][Full Text] [Related]
9. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.
Uberall MA; Stehr K; Cherry JD; Heininger U; Schmitt-Grohé S; Laussucq S; Eckhardt T
Dev Biol Stand; 1997; 89():83-9. PubMed ID: 9272335
[TBL] [Abstract][Full Text] [Related]
10. Association between undervaccination with diphtheria, tetanus toxoids, and acellular pertussis (DTaP) vaccine and risk of pertussis infection in children 3 to 36 months of age.
Glanz JM; Narwaney KJ; Newcomer SR; Daley MF; Hambidge SJ; Rowhani-Rahbar A; Lee GM; Nelson JC; Naleway AL; Nordin JD; Lugg MM; Weintraub ES
JAMA Pediatr; 2013 Nov; 167(11):1060-4. PubMed ID: 24019039
[TBL] [Abstract][Full Text] [Related]
11. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
America Academy of Pediatrics Commitee on Infectious Diseases
Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
[TBL] [Abstract][Full Text] [Related]
12. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.
Knuf M; Habermehl P; Faber J; Bock HL; Sänger R; Bogaerts H; Clemens R; Schuind A; du Prel JB; Schmitt HJ
Vaccine; 2006 Jul; 24(27-28):5627-36. PubMed ID: 16740348
[TBL] [Abstract][Full Text] [Related]
13. Administration of tetanus, diphtheria, and acellular pertussis vaccine to parents of high-risk infants in the neonatal intensive care unit.
Dylag AM; Shah SI
Pediatrics; 2008 Sep; 122(3):e550-5. PubMed ID: 18762489
[TBL] [Abstract][Full Text] [Related]
14. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine.
Barlow WE; Davis RL; Glasser JW; Rhodes PH; Thompson RS; Mullooly JP; Black SB; Shinefield HR; Ward JI; Marcy SM; DeStefano F; Chen RT; Immanuel V; Pearson JA; Vadheim CM; Rebolledo V; Christakis D; Benson PJ; Lewis N;
N Engl J Med; 2001 Aug; 345(9):656-61. PubMed ID: 11547719
[TBL] [Abstract][Full Text] [Related]
15. Safety of a tetanus-diphtheria-acellular pertussis vaccine when used off-label in an elderly population.
Tseng HF; Sy LS; Qian L; Marcy SM; Jackson LA; Glanz J; Nordin J; Baxter R; Naleway A; Donahue J; Weintraub E; Jacobsen SJ;
Clin Infect Dis; 2013 Feb; 56(3):315-21. PubMed ID: 23196953
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous administration of Haemophilus influenzae type b vaccine with acellular or whole-cell pertussis vaccine: effects on reactogenicity and immune responses to pertussis vaccines.
Rennels MB; Reed GF; Decker MD; Edwards KM; Pichichero ME; Deloria MA; Englund JA; Anderson EL; Steinhoff MC; Deforest A
Pediatrics; 1995 Sep; 96(3 Pt 2):576-9. PubMed ID: 7659479
[TBL] [Abstract][Full Text] [Related]
17. Estimating the effectiveness of tetanus-diphtheria-acellular pertussis vaccine (Tdap) for preventing pertussis: evidence of rapidly waning immunity and difference in effectiveness by Tdap brand.
Koepke R; Eickhoff JC; Ayele RA; Petit AB; Schauer SL; Hopfensperger DJ; Conway JH; Davis JP
J Infect Dis; 2014 Sep; 210(6):942-53. PubMed ID: 24903664
[TBL] [Abstract][Full Text] [Related]
18. Acellular pertussis vaccine boosters combined with diphtheria and tetanus toxoid boosters for adolescents: safety and immunogenicity assessment when preceded by different 5-dose DTaP/DTwP schedules.
Pichichero ME; Casey JR; Francis AB; Marsocci SM; Murphy M; Hoeger W; Cleary C
Clin Pediatr (Phila); 2006 Sep; 45(7):613-20. PubMed ID: 16928838
[TBL] [Abstract][Full Text] [Related]
19. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
[TBL] [Abstract][Full Text] [Related]
20. How soon after a prior tetanus-diphtheria vaccination can one give adult formulation tetanus-diphtheria-acellular pertussis vaccine?
Halperin SA; Sweet L; Baxendale D; Neatby A; Rykers P; Smith B; Zelman M; Maus D; Lavigne P; Decker MD
Pediatr Infect Dis J; 2006 Mar; 25(3):195-200. PubMed ID: 16511379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
